CRISPR Therapeutics (NASDAQ:CRSP – Get Rating) had its price objective reduced by equities researchers at Citigroup from $83.00 to $63.00 in a research report issued to clients and investors on Wednesday, The Fly reports. The firm currently has a “neutral” rating on the stock. Citigroup’s target price would indicate a potential upside of 14.48% from the stock’s previous close.
Other research analysts have also recently issued research reports about the company. Stifel Nicolaus raised their price target on CRISPR Therapeutics from $55.00 to $69.00 in a research report on Tuesday, August 9th. Credit Suisse Group decreased their target price on CRISPR Therapeutics from $90.00 to $78.00 in a research report on Wednesday, November 2nd. TheStreet cut CRISPR Therapeutics from a “c” rating to a “d” rating in a research report on Thursday, August 18th. SVB Leerink lifted their target price on CRISPR Therapeutics from $75.00 to $76.00 and gave the company an “outperform” rating in a research report on Monday, November 7th. Finally, Barclays decreased their target price on CRISPR Therapeutics from $88.00 to $61.00 in a research report on Wednesday, November 2nd. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $101.44.
CRISPR Therapeutics Stock Performance
Shares of NASDAQ CRSP opened at $55.03 on Wednesday. CRISPR Therapeutics has a 52 week low of $42.51 and a 52 week high of $86.95. The stock has a market capitalization of $4.31 billion, a P/E ratio of -6.25 and a beta of 1.71. The stock’s fifty day moving average is $58.28 and its 200 day moving average is $64.37.
Insider Buying and Selling
In related news, CEO Samarth Kulkarni sold 25,000 shares of CRISPR Therapeutics stock in a transaction that occurred on Wednesday, September 28th. The stock was sold at an average price of $64.61, for a total value of $1,615,250.00. Following the transaction, the chief executive officer now directly owns 290,279 shares of the company’s stock, valued at $18,754,926.19. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders have sold a total of 75,000 shares of company stock valued at $4,656,500 over the last ninety days. 5.30% of the stock is owned by company insiders.
Hedge Funds Weigh In On CRISPR Therapeutics
Several institutional investors have recently added to or reduced their stakes in CRSP. Signaturefd LLC lifted its stake in CRISPR Therapeutics by 144.5% in the first quarter. Signaturefd LLC now owns 1,809 shares of the company’s stock valued at $114,000 after buying an additional 1,069 shares during the period. Steward Partners Investment Advisory LLC lifted its stake in CRISPR Therapeutics by 155.5% in the first quarter. Steward Partners Investment Advisory LLC now owns 1,796 shares of the company’s stock valued at $113,000 after buying an additional 1,093 shares during the period. National Asset Management Inc. lifted its stake in CRISPR Therapeutics by 3.9% in the first quarter. National Asset Management Inc. now owns 7,329 shares of the company’s stock valued at $461,000 after buying an additional 275 shares during the period. FDx Advisors Inc. lifted its stake in CRISPR Therapeutics by 21.1% in the first quarter. FDx Advisors Inc. now owns 8,598 shares of the company’s stock valued at $540,000 after buying an additional 1,500 shares during the period. Finally, State of New Jersey Common Pension Fund D increased its holdings in shares of CRISPR Therapeutics by 16.0% during the first quarter. State of New Jersey Common Pension Fund D now owns 45,404 shares of the company’s stock valued at $2,850,000 after acquiring an additional 6,263 shares in the last quarter. 70.56% of the stock is owned by institutional investors and hedge funds.
About CRISPR Therapeutics
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
- Get a free copy of the StockNews.com research report on CRISPR Therapeutics (CRSP)
- Microsoft Shares: Is it Time to Back Up the Truck?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Institutional Support for Analog Devices Remains High
- Is the 60/40 Portfolio Mix Still in Vogue?
- Three CBD Stocks to Dominate a Budding Industry
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.